Sun Pharma's $11.75 Billion Organon Bet: Five Stocks That Ride the Wave
Sun Pharmaceutical Industries just announced the largest acquisition in Indian pharma history — a $11.75 billion deal to acquire Organon, the women's health and biosimilars company spun off from Merck. This is not just a Sun Pharma story. It is a signal that Indian pharmaceutical companies have the financial muscle, the operational scale, and the global ambition to compete for marquee assets. Here is what the filings tell us about five companies positioned on the right side of this shift.
The Acquirer's Arsenal
Sun Pharma enters this deal from a position of strength. Per their FY25 annual report, the company delivered consolidated topline growth of 9.0%, with EBITDA growing 17.3% to a margin of 29%. Adjusted net profit rose 19% year-on-year. Their Global Specialty business — the engine that makes this Organon deal strategic — recorded revenue of US$1,216 million in FY25, up 17.1%, led by products like Ilumya in dermatology.
On the balance sheet, Sun Pharma reported cash and cash equivalents of ₹102,688 million as of March 2025, up from ₹92,857 million the prior year, plus ₹107,397 million in mutual fund investments. Current borrowings stood at ₹28,444 million. The company has significant financial headroom to structure this deal through a mix of cash, debt, and equity.
The strategic logic is clear: Organon brings a portfolio of established women's health brands, a growing biosimilars pipeline, and a commercial presence in over 140 countries. Sun Pharma, already present in 100+ countries and ranked as India's largest pharmaceutical company, is building a global platform that rivals mid-tier multinationals.
Cipla: The US Generics Contender
When the market's biggest player is absorbed in a multi-year integration, competitors get room to run. Cipla's filings show exactly why they are positioned to capitalize. Per their FY24 annual report, North America revenue hit an all-time high of USD 906 million, representing 24% year-on-year growth. Cipla is now among the top 15 generic companies in the US by prescriptions, with a strong respiratory portfolio driving base business growth.
By FY25, North America contributed 29% of total revenue, with the domestic business (branded prescriptions, trade generics, and consumer health) making up 42%. Cipla is the second largest player in the Indian pharmaceutical prescription market per IQVIA data. Their growing respiratory franchise — an area where Organon has limited presence — gives them a differentiated position that will not face direct competitive overlap from the combined Sun-Organon entity.
Dr. Reddy's: Scale Meets Momentum
Dr. Reddy's Laboratories has been on a tear. Per their Q2FY25 quarterly results, H1FY25 consolidated revenue reached ₹156.9 billion, up 15% year-on-year, driven by strong performances in North America, India, and Emerging Markets. In Q1FY24, North America revenues surged 79% year-on-year to ₹31,978 million.
The company's FY24 consolidated revenues crossed ₹279.2 billion with 14% growth, and on a re-based comparator (adjusting for divested brands), growth was 16%. Dr. Reddy's broad-based generics pipeline and growing specialty ambitions in the US make them a natural beneficiary of any competitive reshuffling that follows the Sun-Organon integration.
Divi's Laboratories: The API Backbone
Mega-pharma deals drive demand for reliable API manufacturing partners, and Divi's Laboratories is the gold standard. Per their FY23 annual report, Divi's is one of the world's largest API manufacturers, commercially producing 30 Generic APIs at scale — and holding the global number-one position in 10 of them.
Their custom synthesis business serves global pharmaceutical companies, and their backward-integrated manufacturing facilities provide the supply security that post-merger pharmaceutical entities prioritize. As Sun Pharma integrates Organon's product portfolio — spanning established brands and biosimilars — the need for cost-efficient, GMP-compliant API sourcing from trusted Indian manufacturers only grows.
Jubilant Pharmova: The CDMO Play
The contract development and manufacturing (CDMO) sector is the picks-and-shovels bet on pharma globalization. Jubilant Pharmova's FY25 annual report shows their CRDMO segment delivered revenue of ₹11,510 million, up 5%, with EBITDA surging 32% to ₹2,238 million — a significant margin expansion story. They have been scaling their revenue mix toward higher-margin CDMO work and announced a strategic partnership with Pierre Fabre of France to expand into biologics (mAbs) and Antibody-Drug Conjugates (ADCs).
As the chairman's message noted, the company continues to add large pharma clients and scale these contracts. The wave of Indian pharma companies making global acquisitions — Sun Pharma being the largest example — creates demand for India-based CDMO partners who can support portfolio integration and manufacturing consolidation.
Alkem Laboratories: The Biosimilar Dark Horse
Organon's biosimilar business is a key part of the acquisition rationale for Sun Pharma. But Alkem Laboratories has been quietly building its own biosimilar portfolio through subsidiary Enzene Biosciences. Per their H1FY24 quarterly results, Enzene's product suite grew to 7 biosimilar products, including Ranibizumab, and the company received approvals for three monoclonal antibodies in FY23 — Adalimumab, Cetuximab, and Bevacizumab.
Alkem's H1FY24 consolidated revenue from operations reached ₹64,079 million, up 13.3% year-on-year, with the international business (both US and non-US) maintaining robust performance. Their biosimilar portfolio gives them a complementary position: as Sun Pharma focuses on integrating Organon's biosimilar assets globally, Alkem can continue building domestic market share where the Indian biosimilar market is growing at 25-28% CAGR.
What Retail Investors Should Do
The Sun Pharma-Organon deal is a watershed moment for Indian pharma. It signals that the sector has graduated from making $500 million bolt-on acquisitions to bidding for multi-billion-dollar global platforms. Retail investors should watch three things: first, Sun Pharma's deal financing structure when details emerge — heavy debt could pressure margins; second, whether mid-cap peers like Cipla and Dr. Reddy's accelerate their own M&A strategies in response; and third, the order flow to CDMO and API players like Jubilant Pharmova and Divi's Labs in the quarters ahead. The biggest deal in Indian pharma history just raised the bar for the entire sector.
Data sourced from company filings on NSE via Xaro.